Replies to post #10285 on GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

Agree that our CD20 program is a wild card
(we have quite a few of those). It's hard to
keep up with, but here are a couple of apps
from last week for those who are trying:
http://www.freshpatents.com/Anti-cd20-antibodies-and-methods-of-use-dt20080417ptan20080089885.php?type=description
http://www.freshpatents.com/Therapeutic-application-of-chimeric-and-radiolabelled-antibodies-to-human-b-lymphocyte-restricted-differentiation-antigen-for-treatment-of-b-cell-lymphoma-dt20080417ptan20080089893.php?type=description